Testing Shortened Versions of Smell Tests to Screen for Hyposmia in Parkinson's Disease.

Autor:	Auger SD; Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London London United Kingdom., Kanavou S; Population Health Sciences, University of Bristol Bristol United Kingdom., Lawton M; Population Health Sciences, University of Bristol Bristol United Kingdom., Ben-Shlomo Y; Population Health Sciences, University of Bristol Bristol United Kingdom., Hu MT; Oxford Parkinson's Disease Centre University of Oxford Oxford United Kingdom.; Nuffield Department of Clinical Neurosciences University of Oxford Oxford United Kingdom., Schrag AE; Department of Clinical and Movement Neuroscience UCL Institute of Neurology, University College London London United Kingdom., Morris HR; Department of Clinical and Movement Neuroscience UCL Institute of Neurology, University College London London United Kingdom., Grosset DG; Department of Neurology Institute of Neurological Sciences, Queen Elizabeth University Hospital Glasgow United Kingdom., Noyce AJ; Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London London United Kingdom.; Reta Lila Weston Institute and Department of Clinical and Movement Neuroscience UCL Institute of Neurology, University College London London United Kingdom.
Jazyk:	angličtina
Zdroj:	Movement disorders clinical practice [Mov Disord Clin Pract] 2020 Mar 21; Vol. 7 (4), pp. 394-398. Date of Electronic Publication: 2020 Mar 21 (Print Publication: 2020).
DOI:	10.1002/mdc3.12928
Abstrakt:	Background: Hyposmia is an early feature in neurodegenerative diseases, most notably Parkinson's disease (PD). Using abbreviated smell tests could provide a cost-effective means for large-scale hyposmia screening. It is unclear whether short smell tests can effectively detect hyposmia in patient populations. Objectives: To test the ability of short smell combinations to "prescreen" for probable hyposmia in people with PD and target administration of more extensive tests, such as the University of Pennsylvania Smell Identification Test. Methods: We assessed the screening performance of a short 4-smell combination previously derived from use of the 40-item University of Pennsylvania Smell Identification Test in healthy older people and its ability to detect hyposmia in a large cohort of PD patients. Results: The novel 4-smell combination included menthol, clove, onion, and orange and had a sensitivity of 87.1% (95% confidence interval, 84.9%-89.2%) and specificity of 69.7% (63.3%-75.5%) for detecting hyposmia in patients with PD. A different (also novel) 4-item combination developed using a data-driven approach in PD patients only achieved 81.3% (78.2%-84.4%) sensitivity for equivalent specificity. Conclusions: A short 4-smell combination derived from a healthy population demonstrated high sensitivity to detect those with hyposmia and PD. Competing Interests: There was no specific funding for this work. The Preventive Neurology Unit is funded by the Barts Charity. The PREDICT‐PD and Tracking Parkinson's studies are funded by Parkinson's UK. The authors declare that there are no conflicts of interest relevant to this work. (© 2020 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.)
Databáze:	MEDLINE
Externí odkaz: